PE20170705A1 - Nuevos compuestos como inhibidores de ret (reorganizado durante la transfeccion) - Google Patents
Nuevos compuestos como inhibidores de ret (reorganizado durante la transfeccion)Info
- Publication number
- PE20170705A1 PE20170705A1 PE2017000417A PE2017000417A PE20170705A1 PE 20170705 A1 PE20170705 A1 PE 20170705A1 PE 2017000417 A PE2017000417 A PE 2017000417A PE 2017000417 A PE2017000417 A PE 2017000417A PE 20170705 A1 PE20170705 A1 PE 20170705A1
- Authority
- PE
- Peru
- Prior art keywords
- during transfection
- new compounds
- ethoxy
- ret inhibitors
- reorganized during
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/69—Two or more oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
Se refiere al compuesto N-(2-(dimetilamino)etil)-3-(2-(4-(4-etoxi-6-oxo-1,6-dihidropiridin-3-il)-2-fluorofenil)acetamido)-5-(trifluorometil)benzamida, de formula I; y al compuesto N-(3-(2-(dimetilamino)etoxi)-5-(trifluorometil)fenil)-2-(4-(4-etoxi-6-oxo-1,6-dihidropiridin-3-il)-2-fluorofenil)acetamida, de formula II; o una de sus sales farmaceuticamente aceptable de los mismos. Tambien se refiere a una composicion farmaceutica. Dichos compuestos son inhibidores de la cinasa RET (reorganizado durante la transfeccion), siendo utiles en el tratamiento de la normalizacion de la sensibilidad, movilidad y/o secrecion gastrointestinal, enfermedades abdominales, entre otros
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2014086197 | 2014-09-10 | ||
| CN2015086995 | 2015-08-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20170705A1 true PE20170705A1 (es) | 2017-05-21 |
Family
ID=54186249
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2017000417A PE20170705A1 (es) | 2014-09-10 | 2015-09-09 | Nuevos compuestos como inhibidores de ret (reorganizado durante la transfeccion) |
Country Status (36)
| Country | Link |
|---|---|
| US (4) | US9918974B2 (es) |
| EP (2) | EP3517526B1 (es) |
| JP (2) | JP6538154B2 (es) |
| KR (1) | KR20170045350A (es) |
| CN (1) | CN107074768B (es) |
| AU (1) | AU2015313841B2 (es) |
| BR (1) | BR112017004900A2 (es) |
| CA (1) | CA2960768A1 (es) |
| CL (1) | CL2017000588A1 (es) |
| CO (1) | CO2017002273A2 (es) |
| CR (1) | CR20170093A (es) |
| CY (1) | CY1121661T1 (es) |
| DK (1) | DK3191450T3 (es) |
| DO (1) | DOP2017000059A (es) |
| EA (1) | EA033544B1 (es) |
| ES (2) | ES2816453T3 (es) |
| HR (1) | HRP20190815T1 (es) |
| HU (1) | HUE044604T2 (es) |
| IL (1) | IL250908B (es) |
| LT (1) | LT3191450T (es) |
| MA (1) | MA40581A (es) |
| ME (1) | ME03432B (es) |
| MX (1) | MX373863B (es) |
| MY (1) | MY181913A (es) |
| PE (1) | PE20170705A1 (es) |
| PH (1) | PH12017500425A1 (es) |
| PL (1) | PL3191450T3 (es) |
| PT (1) | PT3191450T (es) |
| RS (1) | RS58813B1 (es) |
| SG (1) | SG11201701694QA (es) |
| SI (1) | SI3191450T1 (es) |
| SM (1) | SMT201900304T1 (es) |
| TW (1) | TWI683807B (es) |
| UA (1) | UA122213C2 (es) |
| UY (1) | UY36293A (es) |
| WO (1) | WO2016038552A1 (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011146336A1 (en) | 2010-05-20 | 2011-11-24 | Array Biopharma Inc. | Macrocyclic compounds as trk kinase inhibitors |
| US9879021B2 (en) | 2014-09-10 | 2018-01-30 | Glaxosmithkline Intellectual Property Development Limited | Compounds as rearranged during transfection (RET) inhibitors |
| SMT201900304T1 (it) | 2014-09-10 | 2019-07-11 | Glaxosmithkline Ip Dev Ltd | Derivati piridonici come inibitori della chinasi riarrangiata durante la trasfezione(ret) |
| US10202365B2 (en) | 2015-02-06 | 2019-02-12 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors |
| BR112018000808A2 (pt) | 2015-07-16 | 2018-09-04 | Array Biopharma Inc | compostos de pirazolo[1,5-a]piridina substituída como inibidores de ret cinase |
| EP4331585A3 (en) | 2015-11-02 | 2024-05-15 | Blueprint Medicines Corporation | Inhibitors of ret |
| AR107912A1 (es) | 2016-03-17 | 2018-06-28 | Blueprint Medicines Corp | Inhibidores de ret |
| WO2018017983A1 (en) | 2016-07-22 | 2018-01-25 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to ret |
| JP2018052878A (ja) * | 2016-09-29 | 2018-04-05 | 第一三共株式会社 | ピリジン化合物 |
| TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
| JOP20190077A1 (ar) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret |
| WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
| US11168090B2 (en) | 2017-01-18 | 2021-11-09 | Array Biopharma Inc. | Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| CN110891573A (zh) | 2017-05-15 | 2020-03-17 | 缆图药品公司 | Ret抑制剂和mtorc1抑制剂的组合及其用于治疗由异常ret活性介导的癌症的用途 |
| TWI812649B (zh) | 2017-10-10 | 2023-08-21 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
| TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
| JP6997876B2 (ja) | 2018-01-18 | 2022-02-04 | アレイ バイオファーマ インコーポレイテッド | Ｒｅｔキナーゼ阻害剤としての置換ピラゾリル［４，３－ｃ］ピリジン化合物 |
| JP7060694B2 (ja) | 2018-01-18 | 2022-04-26 | アレイ バイオファーマ インコーポレイテッド | Ｒｅｔキナーゼ阻害剤としての置換ピロロ［２，３－ｄ］ピリミジン化合物 |
| CA3087578C (en) | 2018-01-18 | 2023-08-08 | Array Biopharma Inc. | Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors |
| WO2019195471A1 (en) | 2018-04-03 | 2019-10-10 | Blueprint Medicines Corporation | Ret inhibitor for use in treating cancer having a ret alteration |
| ES2922314T3 (es) | 2018-09-10 | 2022-09-13 | Array Biopharma Inc | Compuestos heterocíclicos condensados como inhibidores de cinasa RET |
| TWI786742B (zh) * | 2020-07-23 | 2022-12-11 | 大陸商深圳晶泰科技有限公司 | 吡啶酮類化合物及其製備方法和應用 |
| AU2023329563A1 (en) | 2022-08-24 | 2025-02-27 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL136767A0 (en) * | 1997-12-22 | 2001-06-14 | Bayer Ag | Inhibition of raf kinase using substituted heterocyclic ureas |
| US20120046290A1 (en) | 1997-12-22 | 2012-02-23 | Jacques Dumas | Inhibition of p38 kinase activity using substituted heterocyclic ureas |
| US20070244120A1 (en) | 2000-08-18 | 2007-10-18 | Jacques Dumas | Inhibition of raf kinase using substituted heterocyclic ureas |
| ATE529109T1 (de) | 1997-12-22 | 2011-11-15 | Bayer Healthcare Llc | Hemmung der p38 kinase aktivität durch substituierte heterocyclische harnstoffe |
| BR0013143A (pt) | 1999-08-12 | 2002-06-11 | Pharmacia Italia Spa | Derivados de 3 (5) amino pirazol, processo para sua preparação e uso dos mesmos como agentes antitumorais |
| CA2430151A1 (en) * | 2000-11-27 | 2002-06-20 | Pharmacia Italia S.P.A. | Phenylacetamido- pyrazole derivatives and their use as antitumor agents |
| DE10201764A1 (de) | 2002-01-18 | 2003-07-31 | Bayer Cropscience Ag | Substituierte 4-Aminopyridin-Derivate |
| AR037647A1 (es) | 2002-05-29 | 2004-12-01 | Novartis Ag | Derivados de diarilurea utiles para el tratamiento de enfermedades dependientes de la cinasa de proteina |
| AU2003264386A1 (en) | 2002-09-10 | 2004-04-30 | Kyorin Pharmaceutical Co., Ltd. | 4-(substituted aryl)-5-hydroxyisoquinolinone derivative |
| EP1658060A2 (en) | 2003-08-22 | 2006-05-24 | Boehringer Ingelheim Pharmaceuticals Inc. | Methods of treating copd and pulmonary hypertension |
| TW200530236A (en) * | 2004-02-23 | 2005-09-16 | Chugai Pharmaceutical Co Ltd | Heteroaryl phenylurea |
| CA2594345C (en) * | 2004-12-28 | 2013-11-05 | Kinex Pharmaceuticals, Llc | Compositions and methods of treating cell proliferation disorders |
| US7968574B2 (en) | 2004-12-28 | 2011-06-28 | Kinex Pharmaceuticals, Llc | Biaryl compositions and methods for modulating a kinase cascade |
| GB0507575D0 (en) * | 2005-04-14 | 2005-05-18 | Novartis Ag | Organic compounds |
| US8247556B2 (en) * | 2005-10-21 | 2012-08-21 | Amgen Inc. | Method for preparing 6-substituted-7-aza-indoles |
| TW200804349A (en) * | 2005-12-23 | 2008-01-16 | Kalypsys Inc | Novel substituted pyrimidinyloxy ureas as inhibitors of protein kinases |
| DK2041071T3 (da) | 2006-06-29 | 2014-09-01 | Kinex Pharmaceuticals Llc | Biarylsammensætninger og fremgangsmåder til modulering af en kinasekaskade |
| CA2662902C (en) * | 2006-09-15 | 2015-11-24 | Xcovery, Inc. | Kinase inhibitor compounds |
| EP2074125A1 (en) * | 2006-10-16 | 2009-07-01 | Novartis Ag | Phenylacetamides useful as protein kinase inhibitors |
| HUE035868T2 (en) * | 2006-11-15 | 2018-05-28 | Ym Biosciences Australia Pty | Inhibitors of kinase activity |
| CN102470127A (zh) | 2009-08-19 | 2012-05-23 | 埃姆比特生物科学公司 | 联芳基化合物和其使用方法 |
| US9073895B2 (en) | 2010-12-16 | 2015-07-07 | Boehringer Ingelheim International Gmbh | Biarylamide inhibitors of leukotriene production |
| CN105051027A (zh) | 2013-03-15 | 2015-11-11 | 葛兰素史密斯克莱知识产权发展有限公司 | 作为转染期间重排(ret)激酶抑制剂的吡啶衍生物 |
| AR095308A1 (es) | 2013-03-15 | 2015-10-07 | Glaxosmithkline Ip Dev Ltd | Compuesto de 2-piridona, composición farmacéutica que lo comprende y su uso para preparar un medicamento |
| US9879021B2 (en) | 2014-09-10 | 2018-01-30 | Glaxosmithkline Intellectual Property Development Limited | Compounds as rearranged during transfection (RET) inhibitors |
| SMT201900304T1 (it) | 2014-09-10 | 2019-07-11 | Glaxosmithkline Ip Dev Ltd | Derivati piridonici come inibitori della chinasi riarrangiata durante la trasfezione(ret) |
-
2015
- 2015-09-09 SM SM20190304T patent/SMT201900304T1/it unknown
- 2015-09-09 UA UAA201703478A patent/UA122213C2/uk unknown
- 2015-09-09 ES ES19160650T patent/ES2816453T3/es active Active
- 2015-09-09 AU AU2015313841A patent/AU2015313841B2/en not_active Ceased
- 2015-09-09 HU HUE15767599 patent/HUE044604T2/hu unknown
- 2015-09-09 JP JP2017513450A patent/JP6538154B2/ja not_active Expired - Fee Related
- 2015-09-09 WO PCT/IB2015/056905 patent/WO2016038552A1/en active Application Filing
- 2015-09-09 CA CA2960768A patent/CA2960768A1/en not_active Abandoned
- 2015-09-09 LT LTEP15767599.2T patent/LT3191450T/lt unknown
- 2015-09-09 CN CN201580058320.5A patent/CN107074768B/zh not_active Expired - Fee Related
- 2015-09-09 PL PL15767599T patent/PL3191450T3/pl unknown
- 2015-09-09 EP EP19160650.8A patent/EP3517526B1/en active Active
- 2015-09-09 EA EA201790546A patent/EA033544B1/ru not_active IP Right Cessation
- 2015-09-09 BR BR112017004900A patent/BR112017004900A2/pt not_active IP Right Cessation
- 2015-09-09 EP EP15767599.2A patent/EP3191450B1/en active Active
- 2015-09-09 MX MX2017003114A patent/MX373863B/es active IP Right Grant
- 2015-09-09 RS RS20190559A patent/RS58813B1/sr unknown
- 2015-09-09 MY MYPI2017700782A patent/MY181913A/en unknown
- 2015-09-09 MA MA040581A patent/MA40581A/fr unknown
- 2015-09-09 DK DK15767599.2T patent/DK3191450T3/da active
- 2015-09-09 ES ES15767599T patent/ES2725704T3/es active Active
- 2015-09-09 CR CR20170093A patent/CR20170093A/es unknown
- 2015-09-09 PT PT15767599T patent/PT3191450T/pt unknown
- 2015-09-09 PE PE2017000417A patent/PE20170705A1/es unknown
- 2015-09-09 ME MEP-2019-136A patent/ME03432B/me unknown
- 2015-09-09 KR KR1020177009237A patent/KR20170045350A/ko not_active Ceased
- 2015-09-09 US US15/509,613 patent/US9918974B2/en not_active Expired - Fee Related
- 2015-09-09 SI SI201530720T patent/SI3191450T1/sl unknown
- 2015-09-09 SG SG11201701694QA patent/SG11201701694QA/en unknown
- 2015-09-10 UY UY0001036293A patent/UY36293A/es unknown
- 2015-09-10 TW TW104129876A patent/TWI683807B/zh not_active IP Right Cessation
-
2017
- 2017-03-02 IL IL250908A patent/IL250908B/en active IP Right Grant
- 2017-03-07 DO DO2017000059A patent/DOP2017000059A/es unknown
- 2017-03-07 PH PH12017500425A patent/PH12017500425A1/en unknown
- 2017-03-07 CO CONC2017/0002273A patent/CO2017002273A2/es unknown
- 2017-03-09 CL CL2017000588A patent/CL2017000588A1/es unknown
-
2018
- 2018-01-23 US US15/877,524 patent/US10111866B2/en not_active Expired - Fee Related
- 2018-09-28 US US16/145,271 patent/US10292975B2/en not_active Expired - Fee Related
-
2019
- 2019-04-05 US US16/376,858 patent/US10709695B2/en not_active Expired - Fee Related
- 2019-05-02 HR HRP20190815TT patent/HRP20190815T1/hr unknown
- 2019-05-09 CY CY20191100502T patent/CY1121661T1/el unknown
- 2019-05-31 JP JP2019102776A patent/JP6728447B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20170705A1 (es) | Nuevos compuestos como inhibidores de ret (reorganizado durante la transfeccion) | |
| CO2019007711A2 (es) | N-[4-fluoro-5-[[(2s,4s)-2-metil-4-[(5-metil-1,2,4-oxadiazol-3-il)metoxi]-1-piperidil]metil]tiazol-2-il]acetamida como inhibidor de oga | |
| HUE059624T2 (hu) | N-(fenil)-2-(fenil)pirimidin-4-karboxamid származékok és rokon vegyületek HPK1-inhibitorokként rák kezelésére | |
| EA201992884A2 (ru) | Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний | |
| AR116394A2 (es) | Mesilato de n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)fenil]acetamida monohidrato | |
| CY1118340T1 (el) | Αναστολεις κινασης | |
| PE20210129A1 (es) | Compuestos de 4-azaindol | |
| MX2018002402A (es) | Compuestos de heteroarilo o arilo biciclicos fusionados como moduladores de la quinasa 4 asociada al receptor de la interleucina 1 (irak4). | |
| UY35998A (es) | 1-(3-(tert-BUTIL)1-(p-TOLIL)-1H-PIRAZOL-5-IL)-3-(4-((2-((6-ETILPIRAZIN-2-IL)AMINO)PIRIDIN-4-IL)METOXI)NAFTALEN-1-IL) UREA Y SUS SALES DERIVADAS FARMACÉUTICAMENTE ACEPTABLES, COMO INHIBIDORES DE P38 M AP QUINASA | |
| PE20151274A1 (es) | Inhibidores de erk y sus usos | |
| PE20151538A1 (es) | Nuevos compuestos como inhibidores de reorganizado durante la transfeccion (ret) | |
| BR112017004673A2 (pt) | formas cristalinas de 2-(4-(4-etoxi-6-oxo-1,6-diidropiridin-3-ila)-2-fluorofenil)-n-(5-(1,1,1-trifluoro-2-metilpropan-2-il)isoxazol-3-il) acetamida | |
| PE20151091A1 (es) | Agentes inductores de apoptosis para el tratamiento de cancer y enfermedades inmunes y autoinmunes | |
| PE20170268A1 (es) | Compuestos de heteroarilo para la inhibicion de cinasa | |
| PE20161416A1 (es) | Derivados de benzamida para la inhibicion de la actividad abl1, abl2 y bcr-abl1 | |
| PE20090423A1 (es) | Compuestos moduladores de sirtuina | |
| PE20140626A1 (es) | Compuestos de bis(fluoroalquil)-1,4-benzodiazepinona | |
| PE20141700A1 (es) | Compuestos de 2-(2,4,5-anilino sustituido) pirimidina | |
| PE20191108A1 (es) | Inhibidores selectivos de jak1 | |
| CY1121421T1 (el) | Φαρμακοτεχνικες μορφες | |
| PE20161225A1 (es) | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer | |
| PE20110062A1 (es) | N-(3-(3,5-dimetoxifenetil)-1h-pirazol-5-il)-4-(3,4-dimetilpiperazin-1-il)benzamida y sales del mismo | |
| PE20161236A1 (es) | Compuesto de triazina y su uso para fines medicos | |
| AR111469A1 (es) | Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma | |
| PE20161393A1 (es) | Heteroaril amidas como inhibidores de agregacion de proteina |